About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Sarcoidosis Vasculitis and Diffuse Lung Diseases
›
top-articles
Sarcoidosis Vasculitis and Diffuse Lung Diseases
0.8
(top 50%)
impact factor
962
(top 20%)
papers
13.0K
(top 20%)
citations
49
(top 10%)
h
-index
0.8
(top 50%)
impact factor
997
all documents
13.4K
doc citations
77
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders
Sarcoidosis Vasculitis and Diffuse Lung Diseases
1999
736
2
The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2014
273
3
Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
1999
231
4
Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2000
201
5
The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2012
168
6
Infliximab for refractory sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2001
164
7
The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2002
131
8
Risk factors of acute exacerbation of idiopathic pulmonary fibrosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2010
129
9
Two year prognosis of sarcoidosis: the ACCESS experience
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2003
122
10
A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2006
118
11
Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2003
97
12
Pulmonary alveolar microlithiasis: report on 576 cases published in the literature
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2004
94
13
Cells and cytokines involved in the pathogenesis of sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
1999
90
14
Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2011
90
15
Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patients
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2003
85
16
Report on the incidence of interstitial lung diseases in Spain
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2004
78
17
Pulmonary hypertension in sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2006
78
18
Inhaled iloprost for sarcoidosis associated pulmonary hypertension
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2009
78
19
Propionibacterium acnes is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2005
75
20
A prospective study of 32 patients with neurosarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2003
73
21
Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2014
69
22
Calcium and vitamin D metabolism in sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2013
68
23
Predicting respiratory failure in sarcoidosis patients
Sarcoidosis Vasculitis and Diffuse Lung Diseases
1997
67
24
Sleep apnea in sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
1997
65
25
Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2002
64
26
Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2011
64
27
Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2009
63
28
Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2013
62
29
Drug-induced pneumonitis: the role of methotrexate
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2001
61
30
Sarcoidosis: genes and microbes--soil or seed?
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2001
60
31
Ambrisentan for sarcoidosis associated pulmonary hypertension
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2011
60
32
Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases
Sarcoidosis Vasculitis and Diffuse Lung Diseases
1997
57
33
Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2008
56
34
Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2009
56
35
Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2014
55
36
Proliferative response of peripheral blood mononuclear cells and levels of antibody to recombinant protein from Propionibacterium acnes DNA expression library in Japanese patients with sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2000
55
37
Use of fluticasone in acute symptomatic pulmonary sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2002
54
38
Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2010
53
39
Endpoints for clinical trials of sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2012
53
40
Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2013
53
41
Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2014
53
42
Treatment and outcome of lung cancer in idiopathic interstitial pneumonias
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2015
53
43
Pulmonary hypertension in idiopathic pulmonary fibrosis: a review
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2009
52
44
Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
1999
51
45
Management of ocular sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2012
51
46
Th1 and Th2 responses regulate experimental lung granuloma development
Sarcoidosis Vasculitis and Diffuse Lung Diseases
1996
50
47
Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
1999
50
48
Sarcoidosis on tattoos: a review of the literature from 1939 to 2011
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2013
50
49
Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2001
49
50
CSF-ACE activity in probable CNS neurosarcoidosis
Sarcoidosis Vasculitis and Diffuse Lung Diseases
2002
49
site/software ©
exaly
; All materials licenced under
CC by-SA
.